开云app官网登录入口网页版-官方正版

#强的松#

26篇内容 | 1724人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2130149, encodeId=805021301493d, content=<a href='/topic/show?id=9c6c91e5784' target=_blank style='color:#2F92EE;'>#试管婴儿#</a>助孕后发生<a href='/topic/show?id=c2383e706b9' target=_blank style='color:#2F92EE;'>#反复种植失败#</a>的患者，口服<a href='/topic/show?id=84065018044' target=_blank style='color:#2F92EE;'>#强的松#</a>不能改善其活产率，反而可能增加<a href='/topic/show?id=9f6a106121b7' target=_blank style='color:#2F92EE;'>#生化妊娠丢失#</a>和<a href='/topic/show?id=5dd75926028' target=_blank style='color:#2F92EE;'>#早产#</a>的风险。, objectTitle=JAMA：颠覆经验性治疗！陈子江/孙贇等合作发现不支持常规使用强的松治疗“反复种植失败”, objectType=article, longId=770159, objectId=147ce7015978, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/busy-reception-in-a-hospital-with-doctors-and-PUPDEB8.jpg, objectUrl=/article/show_article.do?id=147ce7015978, replyNumber=0, likeNumber=103, createdTime=2023-05-05, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=147ce7015978, moduleTitle=JAMA：颠覆经验性治疗！陈子江/孙贇等合作发现不支持常规使用强的松治疗“反复种植失败”, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=147ce7015978)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1756809, encodeId=d9d61e5680930, content=<a href='/topic/show?id=84065018044' target=_blank style='color:#2F92EE;'>#强的松#</a>, objectTitle= Hematol Oncol：鲁索替尼联合强的松、沙利度胺和达那唑治疗骨髓纤维化患者可减少贫血和血小板减少症发生, objectType=article, longId=729566, objectId=040ce2956646, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=040ce2956646, replyNumber=0, likeNumber=73, createdTime=2023-01-10, rootId=0, userName=ms6829001416292975, userId=ee9d37231037, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=040ce2956646, moduleTitle= Hematol Oncol：鲁索替尼联合强的松、沙利度胺和达那唑治疗骨髓纤维化患者可减少贫血和血小板减少症发生, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=040ce2956646)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1756807, encodeId=6e201e5680731, content=<a href='/topic/show?id=84065018044' target=_blank style='color:#2F92EE;'>#强的松#</a>, objectTitle=Sci Rep：静脉冲击注射甲基强的松龙联合小剂量强的松治疗高危IgA肾病, objectType=article, longId=294092, objectId=604929409250, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=604929409250, replyNumber=0, likeNumber=133, createdTime=2022-10-21, rootId=0, userName=ms6829001416292975, userId=ee9d37231037, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=604929409250, moduleTitle=Sci Rep：静脉冲击注射甲基强的松龙联合小剂量强的松治疗高危IgA肾病, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=604929409250)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1756808, encodeId=70c91e5680898, content=<a href='/topic/show?id=84065018044' target=_blank style='color:#2F92EE;'>#强的松#</a>, objectTitle=JAMA Pediatr：上呼吸道感染期间每日小剂量强的松预防复发性激素敏感型肾病综合征复发的疗效评价, objectType=article, longId=301455, objectId=e01c301455ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e01c301455ef, replyNumber=0, likeNumber=88, createdTime=2022-10-06, rootId=0, userName=ms6829001416292975, userId=ee9d37231037, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e01c301455ef, moduleTitle=JAMA Pediatr：上呼吸道感染期间每日小剂量强的松预防复发性激素敏感型肾病综合征复发的疗效评价, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e01c301455ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1756806, encodeId=31d01e56806cd, content=<a href='/topic/show?id=84065018044' target=_blank style='color:#2F92EE;'>#强的松#</a>, objectTitle=AJKD：利妥昔单抗+低剂量环磷酰胺+强的松联合治疗原发性膜性肾病的疗效, objectType=article, longId=221413, objectId=18d1221413ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18d1221413ca, replyNumber=0, likeNumber=93, createdTime=2022-09-19, rootId=0, userName=ms6829001416292975, userId=ee9d37231037, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18d1221413ca, moduleTitle=AJKD：利妥昔单抗+低剂量环磷酰胺+强的松联合治疗原发性膜性肾病的疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=18d1221413ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1756805, encodeId=14c81e56805eb, content=<a href='/topic/show?id=84065018044' target=_blank style='color:#2F92EE;'>#强的松#</a>, objectTitle=Eur Respir J：静脉注射甲基强的松龙脉冲可作为COVID-19严重住院患者的治疗方法, objectType=article, longId=213348, objectId=27bc213348d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=27bc213348d7, replyNumber=0, likeNumber=69, createdTime=2021-10-22, rootId=0, userName=ms6829001416292975, userId=ee9d37231037, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=27bc213348d7, moduleTitle=Eur Respir J：静脉注射甲基强的松龙脉冲可作为COVID-19严重住院患者的治疗方法, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=27bc213348d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1756804, encodeId=d2c81e5680491, content=<a href='/topic/show?id=84065018044' target=_blank style='color:#2F92EE;'>#强的松#</a>, objectTitle=Eur Respir J：静脉注射甲基强的松龙治疗重症COVID-19患者的疗效, objectType=article, longId=200875, objectId=30b82008e56b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=30b82008e56b, replyNumber=0, likeNumber=82, createdTime=2020-10-06, rootId=0, userName=ms6829001416292975, userId=ee9d37231037, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=30b82008e56b, moduleTitle=Eur Respir J：静脉注射甲基强的松龙治疗重症COVID-19患者的疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=30b82008e56b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1756802, encodeId=f0b71e56802a9, content=<a href='/topic/show?id=84065018044' target=_blank style='color:#2F92EE;'>#强的松#</a>, objectTitle=JAMA子刊：COVID-19高烧患者更易发展为ARDS，甲基强的松龙治疗或可降低死亡率, objectType=article, longId=190246, objectId=ad8a19024667, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad8a19024667, replyNumber=0, likeNumber=118, createdTime=2020-03-19, rootId=0, userName=ms6829001416292975, userId=ee9d37231037, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad8a19024667, moduleTitle=JAMA子刊：COVID-19高烧患者更易发展为ARDS，甲基强的松龙治疗或可降低死亡率, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ad8a19024667)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1756803, encodeId=c14b1e568032a, content=<a href='/topic/show?id=84065018044' target=_blank style='color:#2F92EE;'>#强的松#</a>, objectTitle=Prostate Cancer P D：镭-223和恩杂鲁胺或阿比特龙/强的松同时或分层治疗转移去势抵抗性前列腺癌, objectType=article, longId=195245, objectId=a2df19524559, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a2df19524559, replyNumber=0, likeNumber=71, createdTime=2021-02-18, rootId=0, userName=ms6829001416292975, userId=ee9d37231037, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a2df19524559, moduleTitle=Prostate Cancer P D：镭-223和恩杂鲁胺或阿比特龙/强的松同时或分层治疗转移去势抵抗性前列腺癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a2df19524559)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1756800, encodeId=9db81e56800ce, content=<a href='/topic/show?id=84065018044' target=_blank style='color:#2F92EE;'>#强的松#</a>, objectTitle=Eur Urol：醋酸阿比特龙加强的松或恩杂鲁胺治疗对转移去势难治性前列腺癌患者报道结果的影响研究, objectType=article, longId=182264, objectId=060e182264cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=060e182264cd, replyNumber=0, likeNumber=53, createdTime=2020-09-05, rootId=0, userName=ms6829001416292975, userId=ee9d37231037, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=060e182264cd, moduleTitle=Eur Urol：醋酸阿比特龙加强的松或恩杂鲁胺治疗对转移去势难治性前列腺癌患者报道结果的影响研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=060e182264cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1756798, encodeId=8a9f1e56798be, content=<a href='/topic/show?id=84065018044' target=_blank style='color:#2F92EE;'>#强的松#</a>, objectTitle=BMJ：延长强的松龙治疗时间对原发性激素敏感肾病综合征患儿的影响, objectType=article, longId=166853, objectId=10b616685349, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=10b616685349, replyNumber=0, likeNumber=81, createdTime=2019-09-28, rootId=0, userName=ms6829001416292975, userId=ee9d37231037, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=10b616685349, moduleTitle=BMJ：延长强的松龙治疗时间对原发性激素敏感肾病综合征患儿的影响, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=10b616685349)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1756801, encodeId=f40b1e5680182, content=<a href='/topic/show?id=84065018044' target=_blank style='color:#2F92EE;'>#强的松#</a>, objectTitle=Lancet：短期强的松龙治疗手部骨关节炎, objectType=article, longId=182881, objectId=53911828812c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=53911828812c, replyNumber=0, likeNumber=107, createdTime=2020-02-11, rootId=0, userName=ms6829001416292975, userId=ee9d37231037, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=53911828812c, moduleTitle=Lancet：短期强的松龙治疗手部骨关节炎, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=53911828812c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1756799, encodeId=947d1e56799e4, content=<a href='/topic/show?id=84065018044' target=_blank style='color:#2F92EE;'>#强的松#</a>, objectTitle=Neurology：大剂量甲基强的松龙治疗急性创伤性脊髓损伤疗效, objectType=article, longId=176516, objectId=ac0e1e651628, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac0e1e651628, replyNumber=0, likeNumber=70, createdTime=2019-11-01, rootId=0, userName=ms6829001416292975, userId=ee9d37231037, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac0e1e651628, moduleTitle=Neurology：大剂量甲基强的松龙治疗急性创伤性脊髓损伤疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ac0e1e651628)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1756795, encodeId=49641e56795f1, content=<a href='/topic/show?id=84065018044' target=_blank style='color:#2F92EE;'>#强的松#</a>, objectTitle=J Int Adv Otol：先天性突发感官听力损失治疗中，鼓室内甲基强的松龙和地塞米松治疗比较结果分析, objectType=article, longId=155885, objectId=54df15588568, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54df15588568, replyNumber=0, likeNumber=58, createdTime=2019-05-04, rootId=0, userName=ms6829001416292975, userId=ee9d37231037, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54df15588568, moduleTitle=J Int Adv Otol：先天性突发感官听力损失治疗中，鼓室内甲基强的松龙和地塞米松治疗比较结果分析, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=54df15588568)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1756796, encodeId=6ee51e56796bc, content=<a href='/topic/show?id=84065018044' target=_blank style='color:#2F92EE;'>#强的松#</a>, objectTitle=Eur J Cancer：转移去势难治性前列腺癌中，二线药物奥拉他单抗组合米托蒽醌/强的松与米托蒽醌/强的松单独治疗效果比较, objectType=article, longId=157511, objectId=a3f715e5119e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3f715e5119e, replyNumber=0, likeNumber=92, createdTime=2019-12-22, rootId=0, userName=ms6829001416292975, userId=ee9d37231037, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3f715e5119e, moduleTitle=Eur J Cancer：转移去势难治性前列腺癌中，二线药物奥拉他单抗组合米托蒽醌/强的松与米托蒽醌/强的松单独治疗效果比较, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a3f715e5119e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1756797, encodeId=06281e56797a7, content=<a href='/topic/show?id=84065018044' target=_blank style='color:#2F92EE;'>#强的松#</a>, objectTitle=Lancet oncol：ADT疗法联合醋酸阿比特龙和强的松明显高危型转移性前列腺癌患者的总体存活期, objectType=article, longId=164282, objectId=b041164282af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b041164282af, replyNumber=0, likeNumber=81, createdTime=2019-07-21, rootId=0, userName=ms6829001416292975, userId=ee9d37231037, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b041164282af, moduleTitle=Lancet oncol：ADT疗法联合醋酸阿比特龙和强的松明显高危型转移性前列腺癌患者的总体存活期, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b041164282af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1756794, encodeId=607c1e567942a, content=<a href='/topic/show?id=84065018044' target=_blank style='color:#2F92EE;'>#强的松#</a>, objectTitle=Am J Otolaryngol：双边突发性感官神经性听力损失注射强的松失败后鼓室内注射地塞米松效果研究, objectType=article, longId=145454, objectId=e82b1454549e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e82b1454549e, replyNumber=0, likeNumber=67, createdTime=2018-12-18, rootId=0, userName=ms6829001416292975, userId=ee9d37231037, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e82b1454549e, moduleTitle=Am J Otolaryngol：双边突发性感官神经性听力损失注射强的松失败后鼓室内注射地塞米松效果研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e82b1454549e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1756792, encodeId=96e11e56792e4, content=<a href='/topic/show?id=84065018044' target=_blank style='color:#2F92EE;'>#强的松#</a>, objectTitle=Blood：brentuximab vedotin联合环磷酰胺、阿霉素和强的松作为一线治疗方案用于外周T细胞淋巴瘤患者的疗效和安全性, objectType=article, longId=131784, objectId=6781131e84a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6781131e84a3, replyNumber=0, likeNumber=67, createdTime=2018-08-27, rootId=0, userName=ms6829001416292975, userId=ee9d37231037, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6781131e84a3, moduleTitle=Blood：brentuximab vedotin联合环磷酰胺、阿霉素和强的松作为一线治疗方案用于外周T细胞淋巴瘤患者的疗效和安全性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=6781131e84a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1756791, encodeId=72ce1e56791a5, content=<a href='/topic/show?id=84065018044' target=_blank style='color:#2F92EE;'>#强的松#</a>, objectTitle=NEJM：Daratumab、硼替佐米、马法兰和强的松有望成为不可移植多发性骨髓瘤患者的一线治疗方案, objectType=article, longId=129268, objectId=8d621292683e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8d621292683e, replyNumber=0, likeNumber=80, createdTime=2018-12-20, rootId=0, userName=ms6829001416292975, userId=ee9d37231037, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8d621292683e, moduleTitle=NEJM：Daratumab、硼替佐米、马法兰和强的松有望成为不可移植多发性骨髓瘤患者的一线治疗方案, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8d621292683e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1756793, encodeId=6e131e567934e, content=<a href='/topic/show?id=84065018044' target=_blank style='color:#2F92EE;'>#强的松#</a>, objectTitle=Neurology：甲基强的松龙治疗克莱-莱文综合征, objectType=article, longId=133512, objectId=828f133512dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=828f133512dd, replyNumber=0, likeNumber=76, createdTime=2018-06-23, rootId=0, userName=ms6829001416292975, userId=ee9d37231037, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=828f133512dd, moduleTitle=Neurology：甲基强的松龙治疗克莱-莱文综合征, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=828f133512dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

强的松

2020-05-29

侠胆医心 (审核中...)

前往app查看评论内容

#试管婴儿#助孕后发生#反复种植失败#的患者，口服#强的松#不能改善其活产率，反而可能增加#生化妊娠丢失#和#早产#的风险。

JAMA：颠覆经验性治疗！陈子江/孙贇等合作发现不支持常规使用强的松治疗“反复种植失败”

2023-05-05发表于上海

ms6829001416292975 (审核中...)

前往app查看评论内容

#强的松#

Hematol Oncol：鲁索替尼联合强的松、沙利度胺和达那唑治疗骨髓纤维化患者可减少贫血和血小板减少症发生

2023-01-10

ms6829001416292975 (审核中...)

前往app查看评论内容

#强的松#

Sci Rep：静脉冲击注射甲基强的松龙联合小剂量强的松治疗高危IgA肾病

2022-10-21

ms6829001416292975 (审核中...)

前往app查看评论内容

#强的松#

JAMA Pediatr：上呼吸道感染期间每日小剂量强的松预防复发性激素敏感型肾病综合征复发的疗效评价

2022-10-06

ms6829001416292975 (审核中...)

前往app查看评论内容

#强的松#

AJKD：利妥昔单抗+低剂量环磷酰胺+强的松联合治疗原发性膜性肾病的疗效

2022-09-19

ms6829001416292975 (审核中...)

前往app查看评论内容

#强的松#

Eur Respir J：静脉注射甲基强的松龙脉冲可作为COVID-19严重住院患者的治疗方法

2021-10-22

ms6829001416292975 (审核中...)

前往app查看评论内容

#强的松#

Eur Respir J：静脉注射甲基强的松龙治疗重症COVID-19患者的疗效

2020-10-06

ms6829001416292975 (审核中...)

前往app查看评论内容

#强的松#

JAMA子刊：COVID-19高烧患者更易发展为ARDS，甲基强的松龙治疗或可降低死亡率

2020-03-19

ms6829001416292975 (审核中...)

前往app查看评论内容

#强的松#

Prostate Cancer P D：镭-223和恩杂鲁胺或阿比特龙/强的松同时或分层治疗转移去势抵抗性前列腺癌

2021-02-18

ms6829001416292975 (审核中...)

前往app查看评论内容

#强的松#

Eur Urol：醋酸阿比特龙加强的松或恩杂鲁胺治疗对转移去势难治性前列腺癌患者报道结果的影响研究

2020-09-05

ms6829001416292975 (审核中...)

前往app查看评论内容

#强的松#

BMJ：延长强的松龙治疗时间对原发性激素敏感肾病综合征患儿的影响

2019-09-28

ms6829001416292975 (审核中...)

前往app查看评论内容

#强的松#

Lancet：短期强的松龙治疗手部骨关节炎

2020-02-11

ms6829001416292975 (审核中...)

前往app查看评论内容

#强的松#

Neurology：大剂量甲基强的松龙治疗急性创伤性脊髓损伤疗效

2019-11-01

ms6829001416292975 (审核中...)

前往app查看评论内容

#强的松#

J Int Adv Otol：先天性突发感官听力损失治疗中，鼓室内甲基强的松龙和地塞米松治疗比较结果分析

2019-05-04

ms6829001416292975 (审核中...)

前往app查看评论内容

#强的松#

Eur J Cancer：转移去势难治性前列腺癌中，二线药物奥拉他单抗组合米托蒽醌/强的松与米托蒽醌/强的松单独治疗效果比较

2019-12-22

ms6829001416292975 (审核中...)

前往app查看评论内容

#强的松#

Lancet oncol：ADT疗法联合醋酸阿比特龙和强的松明显高危型转移性前列腺癌患者的总体存活期

2019-07-21

ms6829001416292975 (审核中...)

前往app查看评论内容

#强的松#

Am J Otolaryngol：双边突发性感官神经性听力损失注射强的松失败后鼓室内注射地塞米松效果研究

2018-12-18

ms6829001416292975 (审核中...)

前往app查看评论内容

#强的松#

Blood：brentuximab vedotin联合环磷酰胺、阿霉素和强的松作为一线治疗方案用于外周T细胞淋巴瘤患者的疗效和安全性

2018-08-27

ms6829001416292975 (审核中...)

前往app查看评论内容

#强的松#

NEJM：Daratumab、硼替佐米、马法兰和强的松有望成为不可移植多发性骨髓瘤患者的一线治疗方案

2018-12-20

ms6829001416292975 (审核中...)

前往app查看评论内容

#强的松#

Neurology：甲基强的松龙治疗克莱-莱文综合征

2018-06-23

科室
- - 订阅+
  - 更多科室
工具
服务